Comparative diagnostic study of biomarkers using FibroMaxTM and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study

Correspondence: Dina Sabry Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Al Kasr Al Aini Hospital, Al Kasr Al Aini Street, Giza, Egypt Tel +20 11 1120 0200 Fax +1 202 2363 2297 Email [email protected] Background: Steatosis is common in patients with hepatitis C virus (HCV) infection and may be a major determinant of progression of liver injury. This study evaluated FibroMaxTM for noninvasive diagnosis of steatosis in patients with chronic HCV. Methods: This cross-sectional study included 44 patients naïve to treatment who were referred to our hepatology clinic for assessment of fitness for antiviral therapy. Chronic HCV infection was diagnosed by viral markers. Investigations included assessment of abdominal ultrasonography, liver biopsy, calculation of body mass index, and biomarker parameters in serum using FibroMax. Results: Histopathology of liver biopsies showed steatosis in 30 of 44 (68%) patients. FibroMax results were positively correlated with viral load by quantitative polymerase chain reaction and histopathological findings. Body mass index was significantly higher in steatotic patients (P = 0.003) and was significantly associated with the results on FibroMax (P = 0.005). Conclusion: FibroMax was correlated with histopathology and body mass index in patients with HCV. Abdominal ultrasonography could not be used as a single tool to diagnose steatosis with HCV. Steatosis is correlated with viral load, which suggests a direct viral effect. We recommend FibroMax assessment in a larger number of patients to assess its applicability in patients with HCV and steatosis.